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This is the first study to investigate the
efficacy of intravenous iron in treating
fatigue in nonanemic patients with low
serum ferritin concentration. In a random-
ized, double-blinded, placebo-controlled
study, 90 premenopausal women pre-
senting with fatigue, serum ferritin
< 50 ng/mL, and hemoglobin > 120 g/L
were randomized to receive either 800 mg
of intravenous iron (III)–hydroxide su-
crose or intravenous placebo. Fatigue
and serum iron status were assessed at
baseline and after 6 and 12 weeks. Me-
dian fatigue at baseline was 4.5 (on a
0-10 scale). Fatigue decreased during the
initial 6 weeks by 1.1 in the iron group
compared with 0.7 in the placebo group
(P  .07). Efficacy of iron was bound to
depleted iron stores: In patients with base-
line serum ferritin < 15 ng/mL, fatigue
decreased by 1.8 in the iron group com-
pared with 0.4 in the placebo group
(P  .005), and 82% of iron-treated com-
pared with 47% of placebo-treated pa-
tients reported improved fatigue (P  .03).
Drug-associated adverse events were
observed in 21% of iron-treated patients
and in 7% of placebo-treated patients
(P  .05); none of these events was seri-
ous. Intravenous administration of iron
improved fatigue in iron-deficient, non-
anemic women with a good safety and
tolerability profile. The efficacy of intrave-
nous iron was bound to a serum ferritin
concentration < 15 ng/mL. This study
was registered at the International
Standard Randomized Controlled Trial
Number Register (www.isrctn.org) as
ISRCTN78430425. (Blood. 2011;118(12):
3222-3227)
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Learning objectives
Upon completion of this activity, participants will be able to:
1. Describe the effects of intravenous iron on fatigue and on ferritin concentrations, on the basis of findings of a randomized
controlled trial in nonanemic, premenopausal women.
2. Describe the adverse effects of intravenous iron, on the basis of findings of this randomized controlled trial in nonanemic,
premenopausal women.
3. Describe clinical implications of these findings.
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Introduction
Fatigue is a common symptom in general practice, affecting up to
one-third of the population.1-5 Similarly, iron deficiency is a
disorder affecting approximately one-fourth of menstruating women,
as indicated by a French survey defining iron deficiency as serum
ferritin concentrations below 15 ng/mL.6-8 Women are particularly
at risk of developing either or both of these conditions.9,10
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Several studies have suggested that iron deficiency can cause
fatigue symptoms.11-13 Clinical studies indicate an association
between the status of body iron stores and aerobic adaptation
during exercise14-16 as well as with cognitive function.17,18 Re-
cently, Anker et al demonstrated that intravenous iron improved
clinical disease, functional capacity, and quality of life in iron-
deficient, nonanemic patients with chronic heart failure.14
Verdon et al demonstrated that oral iron supplementation
improved fatigue in a subgroup of premenopausal nonanemic
women with iron deficiency.13 Beutler et al showed that women
with normal hemoglobin concentration but depleted or reduced
bone marrow iron stores experienced improvements in fatigue after
oral iron therapy.11 However, oral iron administration has limita-
tions: it is often accompanied by gastrointestinal side effects and
only 10% of orally administered iron is absorbed by the body.6
Investigation of any therapeutic approach to reducing fatigue
can be influenced by a strong placebo effect,19 making a placebo-
controlled and blinded study design essential for drawing conclu-
sions relevant for medical practice. Prior studies analyzing the
effect of iron supplementation on fatigue improvement were
performed with oral iron, which can result in an unintended
unblinding of patients because of intestinal side effects and stool
coloring and thus influence study results. This is the first study to
investigate the efficacy of intravenous iron in the treatment of
fatigue in nonanemic female patients with low serum ferritin
concentration.
Methods
The FERRIM trial was conducted at 4 study centers in Switzerland (Policlinic of
Internal Medicine, University Hospital Basel; Division of Internal Medicine,
University Hospital Zurich; Gynaekologie & Geburtshilfe, Seefeld, Zurich; and
Ambulatorium Wiesendamm, Basel) in accordance with the Declaration of
Helsinki and the Guidelines on Good Clinical Practice. The protocol and all
amendments were approved by the local ethics committees at the centers. All
patients included in the study gave written informed consent. This study was
registered at International Standard Randomized Controlled Trial Number
Register (www.isrctn.org) as ISRCTN78430425.
Inclusion and exclusion criteria
Premenopausal, menstruating women 18 years of age who presented
with fatigue were evaluated for inclusion in the study. Inclusion criteria
were serum ferritin concentration 50 ng/mL, hemoglobin concentra-
tion  120 g/L, and adequate contraception for the study period. Exclusion
criteria were pregnancy, intake of gestagens repressing menstruation,
physical or mental disorders, medication affecting physical or mental
performance, iron treatment in the 4 weeks before enrollment, and history
of hypersensitivity to any iron medication. Patients were withdrawn from
the study if serum ferritin concentration exceeded 800 ng/mL or if
transferrin saturation exceeded 50% during the study period.20
Study design
The FERRIM trial was a randomized, double-blinded, placebo-controlled
study. Patients were randomized to receive either a cumulative intravenous
dose of 800 mg of iron as iron (III)–hydroxide sucrose or intravenous
placebo for 2 weeks. The primary study objective was to determine the
efficacy of iron compared with placebo in decreasing fatigue 6 weeks after
treatment initiation. Secondary objectives were to determine the impact of
iron supplementation on serum ferritin and hemoglobin concentration and
to confirm the safety of intravenous iron sucrose. Patients were followed up
for 12 weeks. Subgroups of the study population were analyzed to
investigate the influence of the serum iron status at baseline on the efficacy
of iron treatment.
Randomization and blinding
The randomization schedule was generated by Cardinal Health Germany
GmbH (Schorndorf, Germany). In total, 172 randomization numbers were
generated.
The control group received placebo (0.9% saline). It was ensured
through organizational measures that neither the patient nor the investigator
could become aware of whether the active group (dark-brown solution) or
Figure 1. Study flow diagram.
Figure 2. Fatigue at baseline and after 6 weeks in the iron-treated and the
placebo-treated group (dotted lines correspond to medians).
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placebo (colorless solution) was administered. The study medication was
prepared and administered by a staff member other than the investigator.
Both the infusion bag and the injection site were covered and nontranspar-
ent tubing was used, ensuring that the patient could not see the infusion
solution at any time. The investigator was not present during the infusion.
Study medication
Treatment was delivered for 4 days during the first 2 weeks of the study by a
physician’s assistant who injected either 4 infusions containing 200 mg of
iron as iron (III)–hydroxide sucrose (Venofer; Vifor Pharma) in 200 mL of
0.9% saline or 4 infusions of 200 mL of 0.9% saline over a minimum period
of 10 minutes each. The physician’s assistant took all necessary precautions
to ensure that the patient could not see nor draw any conclusion as to the
nature of the solution administered. The work of the physician’s assistant
was done completely independently of the study physicians.
Fatigue scores
Fatigue was assessed at baseline, and after 6 and 12 weeks using the Brief
Fatigue Inventory questionnaire (BFI).21,22 Patients were asked to rate the
severity of fatigue on a scale from 0 (no fatigue) to 10 (maximum
imaginable fatigue) by answering standardized questions. Three questions
addressed the level of fatigue at its worst, its usual, and its current level
during the last 24 hours; 6 questions were aimed at gauging the interference
of fatigue with aspects of daily life, including general activity, mood,
walking ability, work/housework, relations with other people, and enjoy-
ment of life. According to the original publication validating the BFI, total
fatigue score was obtained by calculating the mean of the resulting scores
for these questions.21,22
In addition, change in fatigue was assessed 6 and 12 weeks after
treatment initiation by the Short Performance Inventory (SPI) question-
naire. Patients were asked to categorize their current level of fatigue
compared with the situation at baseline as improved (slightly better, much
better, or completely resolved) or not improved.
Laboratory parameters
The concentrations of hemoglobin, iron, serum ferritin, transferrin, and
C-reactive protein were measured at baseline and after 6 and 12 weeks.
Levels of creatinine, alanine aminotransferase, aspartate aminotransferase,
and thyroid-stimulating hormone were determined at baseline. Analyses
were done in a central laboratory (Rothen Medizinische Laboratorien,
Basel, Switzerland).
Adverse events
Adverse events were reported by the patients or assessed by the study physicians
at each visit. Adverse events were classified as “serious” or “not serious” and as
“drug-associated” or “not drug-associated.” All patients who received at least 1
dose of study medication were included in the analysis.
Statistical analysis
Results with parametric distribution are presented as mean values ( 1 SD)
and results with nonparametric distribution as median values (quartiles Q1,
Q3). Comparisons between the study groups were performed with the t test,
the Mann-Whitney U test, or the 2 test. Correlations were determined
according to the method of Pearson. Intention-to-treat analysis included all
patients randomized and patients treated at least once and with at least one
post-baseline evaluation according to the study protocol. Missing values
were imputed according to the baseline observation and the last observation
carried forward principle.23 All tests were performed double-sided with a
significance level of 5% (P  .05).
Results
Study population and baseline characteristics
Of 116 premenopausal women presenting with fatigue, 90 were
included in the study. Median fatigue score of the study population
was 4.5 at baseline as assessed on a scale from 0-10 using the BFI
questionnaire. The majority of study patients presented with fatigue
levels previously defined as “low” or “moderate.”21,22 Of the
90 patients, 43 (48%) were randomized to receive intravenous iron
(4  200 mg iron as iron [III]–hydroxide sucrose) and 47 (52%) to
receive intravenous placebo (4 200 mL of 0.9% saline). Forty-
two iron-treated patients and 44 placebo-treated patients underwent
postbaseline evaluation (Figure 1).
At baseline, there was no significant difference between the
iron and the placebo group with regard to fatigue (4.0 vs 4.7, P .10),
serum ferritin concentration (24 vs 20 ng/mL, P .10), or transferrin
saturation (20 vs 25%, P .10). The study groups were also well
randomized with regard to age, height, body weight, blood pressure,
heart rate, and laboratory parameters (Figure 2 and Table 1).
Change in fatigue after 6 weeks
Fatigue decreased in both study groups during the first 6 weeks
after treatment initiation as assessed by the BFI score (Figure 2).
After 6 weeks, median fatigue decreased by 1.1 in the iron group
and by 0.7 in the placebo group (P  .07; Table 2).
Improvement in fatigue 6 weeks after the start of treatment, as
evaluated by the SPI, was reported by 65% of iron-treated and
40% of placebo-treated patients (P  .02; Table 2). The most
prominent difference between the 2 study groups was observed in
those patients who judged their fatigue to be “much better” after
6 weeks of treatment. These patients comprised 28% of the iron
group but only 13% of the placebo group (Table 2).
Change in iron status after 6 weeks
In iron-treated patients, a significant increase in serum ferritin
concentration (98 ng/mL vs 1 ng/mL; P  .001) and transferrin
saturation (9% vs 2%; P  .006) was observed during the 6 weeks
after treatment initiation compared with placebo-treated patients
(Table 2). In contrast, hemoglobin levels remained normal and
constant in both study groups during this period. As an inflamma-
tion marker, C-reactive protein remained stable in both groups
throughout the study period.
Efficacy of iron treatment in subgroups
The World Health Organization (WHO) has defined a cutoff serum
ferritin concentration of 15 ng/mL to identify iron deficiency.24





Age, y 31  8 32  7 ns
Height, cm 166  6 166  6 ns
Body weight, kg 60  8 59  7 ns
Blood pressure systolic, mmHg 117  13 117  13 ns
Blood pressure diastolic, mmHg 73  8 72  10 ns
Heart rate, 1/min 72  10 71  9 ns
Hemoglobin, g/L 133  6 133  7 ns
Mean red blood cell volume, fl 90  5 90  5 ns
Serum ferritin concentration, ng/mL 24 (10, 32) 20 (14, 28) ns
Transferrin saturation, % 20 (14, 30) 25 (16, 32) ns
Creatinine, mol/L 77 (72, 82) 78 (72, 84) ns
Alanine aminotransferase, U/L 17 (13, 21) 17 (15, 23) ns
Aspartate aminotransferase, U/L 20 (17, 26) 21 (18, 24) ns
Thyroid-stimulating hormone, mU/L 1.5 (1.0, 2.0) 1.4 (0.8, 2.0) ns
C-reactive protein, mg/L 1.1 (1.1, 1.1) 1.1 (1.1, 1.1) ns
Results are presented as means  1 SD or as median values (quartiles Q1, Q3).
P values were calculated by t test or the Mann-Whitney U test.
ns indicates not significant and no trend (P  .10).
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Therefore, in an additional analysis, the WHO criterion was applied
to the present study. The efficacy of iron was evaluated in
the subgroups of patients with serum ferritin concentration
 15 ng/mL (n 34) and 15 ng/mL (n  56) at baseline.
Further analysis was performed in patients with transferrin satura-
tion 20% and 20% at baseline.
Among patients with a baseline serum ferritin concentra-
tion 15 ng/mL (n 34), median fatigue according to the BFI
score decreased by 1.8 in the iron group compared with 0.4 in the
placebo group (P  .005; Figure 3 and Table 3). An improvement
in fatigue, as assessed by the SPI, was reported by 82% of
iron-treated patients compared with 47% of placebo-treated pa-
tients (P  .03; Table 3). No significant differences between the
study groups in BFI or SPI score at 6 weeks were observed in
patients with baseline serum ferritin 15 ng/mL (Table 3).
Similarly, in patients with transferrin saturation 20% at
baseline, administration of iron resulted in a significantly greater
reduction in fatigue than administration of placebo (BFI, P  .01;
SPI, P  .002). However, patients with transferrin satura-
tion 20% experienced no significant reduction in fatigue (both
questionnaires, P  .10).
Follow-up after 12 weeks
The decrease in fatigue (BFI) between baseline and 12 weeks was
1.3 in the iron group and 0.9 in the placebo group (P  .1), and
improvement in fatigue (SPI) was reported by 63% of iron-treated
patients and by 34% of placebo-treated patients (P  .006).
Improvements in serum ferritin concentration and transferrin
saturation in iron-treated compared with placebo-treated patients
remained significant after 12 weeks (P  .001 and P  .006,
respectively; Table 4).
Among patients with a baseline serum ferritin concentra-
tion 15 ng/mL, the median decrease in fatigue score between
baseline and 12 weeks was 2.3 and 0.7 in the iron and the placebo
groups, respectively (P  .03). Improvement in fatigue was
reported by 82% of iron-treated patients and by 35% of placebo-
treated patients (P  .005; Table 4).
Adverse events
Evaluation of adverse events was performed throughout the study
period and included 89 patients who each received at least one dose
of study medication. The study groups did not differ significantly in
the number of patients reporting adverse events or in the number of
adverse events per patient (Table 5). One serious adverse event was
observed in the iron group (appendicitis) and one in the placebo
Table 2. Change of fatigue and laboratory parameters 6 weeks after treatment initiation with intravenous iron or intravenous placebo
Iron group Placebo group P
Change in fatigue (BFI)
n  90, ITT all patients randomized 	1.1 (	2.2, 	0.3) 	0.7 (	1.3, 0.0) .07
n  86, ITT according to protocol* 	1.1 (	2.2, 	0.4) 	0.8 (	1.4, 0.0) .08
Fatigue improved (SPI), n (%) 28/43 (65%) 19/47 (40%) .02
Fatigue slightly better 12 (28%) 9 (19%)
Fatigue much better 12 (28%) 6 (13%)
Fatigue completely resolved 4 (9%) 4 (8%)
Change in laboratory parameters
Serum ferritin concentration, ng/mL 98 (74, 113) 1 (	7, 5)  .001
Transferrin saturation, % 9 (0, 23) 2 (	5, 9) .006
Haemoglobin, g/L 1  7 0  6 ns
C-reactive protein, mg/L 0 (0, 0) 0 (0, 0) ns
Results are presented as means  1 SD, median values (quartiles Q1, Q3), or number of patients (%). P values were calculated with the t test, the Mann Whitney U test, or
the 2 test.
ns indicates not significant and no trend (P  .10); and ITT, intention-to-treat analysis.
*Analysis included all patients treated at least once and with at least 1 postbaseline evaluation.
Figure 3. Change of fatigue in patients with baseline ferritin < 15 ng/mL
depending on the administration of iron or placebo (P  .005).
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group (traffic accident). Neither was classified as being drug
associated.
Seventeen drug-associated adverse events were reported among
9 patients treated with intravenous iron, whereas 4 drug-associated
adverse events were reported among 3 placebo-treated patients
(Table 5). The difference between the study groups was significant
regarding the number of patients reporting drug-associated adverse
events (P  .05). However, none of these drug-associated events
was considered serious—the most frequently observed were nau-
sea, chills, and headache (Table 5). The occurrence of these
drug-associated adverse events was limited to the period of drug
administration.
Discussion
This randomized, double-blinded, placebo-controlled study investi-
gated for the first time the efficacy and safety of intravenous iron
therapy in the treatment of fatigue in premenopausal nonanemic
(hemoglobin 120 g/L) women with low serum ferritin concentra-
tion ( 50 ng/mL). A significant effect of iron (compared with
placebo) on fatigue was observed exclusively in patients with
substantially depleted iron stores, as indicated by a serum ferritin
concentration 15 ng/mL at baseline. More than 80% of these
patients reported improved fatigue 6 and 12 weeks after treatment
initiation, as well as decreases in the severity of fatigue to less than
half of the initial value at study completion. These are the first
results providing evidence that intravenous supplementation of iron
can improve fatigue symptoms in iron-deficient, nonanemic pre-
menopausal women.
In the present study, serum ferritin concentration 15 ng/mL
or transferrin saturation 20% (with serum ferritin concentra-
tion 50 ng/mL) were predictive for a significant benefit from
intravenous iron therapy. Of these criteria, serum ferritin concentra-
tion 15 ng/mL is probably more suitable for use in general
practice. However, the size of the study population does not allow
definitive determination of a cutoff serum ferritin concentration
below which patients benefit from iron therapy.
A total dose of 800 mg of intravenous iron administered over
2 weeks resulted in a marked increase in serum ferritin concentra-
tion (98 ng/mL), which indicated sufficient replenishment of body
iron stores. Iron administration, however, did not influence hemo-
globin concentration, which was in the normal range at baseline
and remained constant during the observation period in both
iron-treated and placebo-treated patients. Therefore, the fatigue-
reducing effects of iron therapy reflect the nonhematological
functions of iron. Iron is an essential component of a large number
of human metabolic enzymes, including ribonucleotide reductase,
NADH dehydrogenase, succinate dehydrogenase, and cytochrome
c reductase/oxidase. These enzymes catalyze essential biochemical
reactions such as the formation of deoxyribonucleotides and
aerobic oxidation of carbohydrates and fatty acids in the mitochon-
drial citric acid cycle and the respiratory chain.25-27
The results of this study are in agreement with previous studies
indicating a beneficial effect of oral iron therapy in comparable
patient groups.11-13,18 Oral iron treatment, however, can be accom-
panied by gastrointestinal side effects and usually requires adminis-
tration over several months because intestinal iron absorption is
low6; both of these factors affect patients’ adherence to therapy. In
contrast, intravenous iron can efficaciously replenish iron stores
with a good safety and tolerability profile.14 In the present study,
drug-associated adverse events were observed more frequently in
iron-treated (21%) than placebo-treated (7%) patients. However,
these events (mainly nausea, chills, and headache) were not serious
and occurrence was limited to the period of administration.
Improvement in fatigue after 6 weeks was reported by 40% of
placebo-treated patients. Further evaluation of this strong placebo
effect showed a significant correlation between baseline fatigue
and decrease in fatigue (r 0.38, P  .009): patients with high
initial fatigue showed a strong response to placebo. This highlights
the importance of the emotional component of fatigue in patients
who considered themselves to be severely fatigued.21,22 This
observation may be accurate for the iron-deficient, otherwise
healthy study population but not necessarily for other populations,
such as patients suffering from fatigue as a result of cancer.
Table 4. Change in fatigue and serum iron status 12 weeks after treatment initiation with intravenous iron or intravenous placebo
Iron group Placebo group P
Total study population (n  90)
Change of fatigue (BFI), median 	1.3 (	2.4, 	0.5) 	0.9 (	2.2, 0.0) ns
Fatigue improved (SPI), n (%) 27/43 (63%) 16/47 (34%) .006
Change of ferritin concentration, ng/mL 81 (49, 100) 	1 (	7, 4)  .001
Change of transferrin saturation, % 7 (0, 17) 1 (5, 6) .006
Population with baseline ferritin < 15 ng/mL (n  34)
Change of fatigue (BFI), median 	2.3 (	3.2, 0.9) 	0.7 (	1.3, 0.1) .03
Fatigue improved (SPI), n (%) 14/17 (82%) 6/17 (35%) .005
Results are presented as median values (quartiles Q1, Q3) or number of patients (%). P values were calculated with the Mann Whitney U test or the 2 test.
ns indicates not significant and no trend (P  .10).
Table 3. Change in fatigue 6 weeks after treatment initiation with intravenous iron or intravenous placebo in dependence of the serum
ferritin concentration at baseline
Iron group Placebo group P
Baseline ferritin < 15 ng/mL (n  34)
Change of fatigue (BFI), median 	1.8 (	2.5, 	0.8) 	0.4 (	1.2, 0.0) .005
Fatigue improved (SPI), n (%) 14/17 (82%) 8/17 (47%) .03
Baseline ferritin > 15 ng/mL (n  56)
Change of fatigue (BFI), median 	0.7 (	1.8, 0.0) 	0.8 (	1.4, 0.0) ns
Fatigue improved (SPI), n (%) 14/26 (54%) 11/30 (37%) ns
Results are presented as median values (quartiles Q1, Q3) or number of patients (%). P values were calculated with the Mann Whitney U test or the 2 test.
ns indicates not significant and no trend (P  .10).
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It is always recommended to carefully search for somatic,
psychological, and/or social causes of fatigue. Even if a low serum
ferritin value is found, a serious cause of iron deficiency such as
gastrointestinal bleeding, malabsorption syndrome, or gynecologi-
cal diseases must be considered even in premenopausal women.
In conclusion, in the present study, intravenous administration
of 800 mg of iron improved fatigue in iron-deficient, nonanemic
women with a good safety and tolerability profile. Response to iron
was bound to the degree of depletion of iron stores, as indicated by
a serum ferritin concentration 15 ng/mL before treatment. Inves-
tigation in a larger population is needed to confirm the conditions
under which patients benefit from iron therapy.
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Table 5. Adverse events
Iron group Placebo group P
All adverse events
Number of patients reporting
events, n (%)
23 (53%) 31 (66%) ns
Total number of adverse events, n 52 53 ns
Number of serious adverse events, n 1 1
Appendicitis 1 0
Traffic accident 0 1
Drug-associated adverse events
Number of patients reporting events, n 9 (21%) 3 (7%) .05









P values were calculated with the 2 test or the Mann Whitney U test (number of
events per patient).
ns indicates not significant and no trend (P  .10).
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